{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:20:24Z","timestamp":1791958824684,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020908","name":"Pfizer SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020908","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.idnow.2025.105036","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T23:23:48Z","timestamp":1739057028000},"page":"105036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-world use, effectiveness, and safety of ceftazidime-avibactam: Results of the French cohort OZAVIE"],"prefix":"10.1016","volume":"55","author":[{"given":"Lionel","family":"Piroth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Vitrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Le","family":"Moing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2305-5387","authenticated-orcid":false,"given":"Yves","family":"Brault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Charlotte","family":"Chopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-5705","authenticated-orcid":false,"given":"Philippe","family":"Montravers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Tattevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Bleibtreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.idnow.2025.105036_b0005","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3390\/microorganisms11071798","article-title":"Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review","volume":"11","author":"Venuti","year":"2023","journal-title":"Microorganisms"},{"issue":"4","key":"10.1016\/j.idnow.2025.105036_b0010","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/CCM.0b013e31819ced02","article-title":"Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit","volume":"37","author":"Shorr","year":"2009","journal-title":"Crit Care Med"},{"issue":"6","key":"10.1016\/j.idnow.2025.105036_b0015","doi-asserted-by":"crossref","first-page":"e1571","DOI":"10.1002\/wsbm.1571","article-title":"Molecular mechanisms underlying bacterial resistance to ceftazidime\/avibactam","volume":"14","author":"Xiong","year":"2022","journal-title":"WIREs Mech Dis"},{"issue":"1","key":"10.1016\/j.idnow.2025.105036_b0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13613-023-01155-4","article-title":"The place of new antibiotics for Gram-negative bacterial infections in intensive care: report of a consensus conference","volume":"13","author":"Dequin","year":"2023","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.idnow.2025.105036_b0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","article-title":"Resistance to ceftazidime-avibactam and underlying mechanisms","volume":"22","author":"Wang","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.idnow.2025.105036_b0030","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.2147\/IDR.S387187","article-title":"Emergence of Ceftazidime-Avibactam Resistance and Decreased Virulence in Carbapenem-Resistant ST11 Klebsiella pneumoniae During Antibiotics Treatment","volume":"15","author":"Xu","year":"2022","journal-title":"Infect Drug Resist"},{"issue":"3","key":"10.1016\/j.idnow.2025.105036_b0035","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40121-023-00762-9","article-title":"The Use and Effectiveness of Ceftazidime-Avibactam in Real-World Clinical Practice: EZTEAM Study","volume":"12","author":"Soriano","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"6","key":"10.1016\/j.idnow.2025.105036_b0040","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jiph.2023.04.014","article-title":"Efficacy and mortality of ceftazidime\/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study","volume":"16","author":"Zhuang","year":"2023","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.idnow.2025.105036_b0045","article-title":"Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Open Forum","author":"Jorgensen","year":"2019612522","journal-title":"Infect Dis"},{"issue":"1","key":"10.1016\/j.idnow.2025.105036_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.107021","article-title":"Clinical efficacy of ceftazidime\/avibactam combination therapy for severe hospital-acquired pulmonary infections caused by carbapenem-resistant and difficult-to-treat Pseudomonas aeruginosa","volume":"63","author":"Xu","year":"2024","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.idnow.2025.105036_b0055","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idnow.2025.105036_b0060","article-title":"Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections","author":"Tamma","year":"2024403","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.idnow.2025.105036_b0065","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idnow.2025.105036_b0070","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/dkaa503","article-title":"Ceftazidime\/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study","volume":"76","author":"Karaiskos","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2025.105036_b0075","doi-asserted-by":"crossref","unstructured":"H.F. Sanz, Ceftazidime-avibactam. Rev Esp Quimioter. 2022;35 Suppl 1(Suppl 1):40-42. doi: 10.37201\/req\/s01.09.2022.","DOI":"10.37201\/req\/s01.09.2022"},{"issue":"1","key":"10.1016\/j.idnow.2025.105036_b0080","doi-asserted-by":"crossref","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-Lactam-\u03b2-Lactamase Inhibitor Combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.idnow.2025.105036_b0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13613-023-01153-6","article-title":"Rationale and evidence for the use of new beta-lactam\/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients","volume":"13","author":"Barbier","year":"2023","journal-title":"Ann Intensive Care"},{"issue":"1","key":"10.1016\/j.idnow.2025.105036_b0090","first-page":"453","article-title":"Best practices: Appropriate use of the new \u03b2-lactam\/\u03b2-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa","volume":"37","author":"Brink","year":"2022","journal-title":"S Afr J Infect Dis"},{"issue":"6","key":"10.1016\/j.idnow.2025.105036_b0095","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3855\/jidc.17290","article-title":"Synergistic combination of aztreonam and ceftazidime\/avibactam against resistant Stenotrophomonas maltophilia on pancreatitis","volume":"17","author":"De Almeida","year":"2023","journal-title":"J Infect Dev Ctries"},{"issue":"7","key":"10.1016\/j.idnow.2025.105036_b0100","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1080\/1120009X.2023.2247199","article-title":"Looking for Stenotrophomonas maltophilia treatment: invitro activity of ceftazidime\/avibactam alone and in combination with aztreonam","volume":"35","author":"Ranieri","year":"2023","journal-title":"J Chemother"},{"issue":"11","key":"10.1016\/j.idnow.2025.105036_b0105","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-\u03b2-lactamase-Producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idnow.2025.105036_b0110","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s11739-023-03416-3","article-title":"Clinical outcomes in elderly patients with infections caused by NDM-producing Klebsiella pneumoniae: results from a real-life retrospective single center study in an endemic area","volume":"18","author":"Mura","year":"2023","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.idnow.2025.105036_b0115","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections","author":"Shields","year":"201663121615","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idnow.2025.105036_b0120","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jgar.2021.04.001","article-title":"Resistance to ceftazidime\/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies","volume":"25","author":"Di Bella","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"issue":"6","key":"10.1016\/j.idnow.2025.105036_b0125","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijantimicag.2019.08.025","article-title":"Efficacy of ceftazidime\/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis","volume":"54","author":"Onorato","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.idnow.2025.105036_b0130","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","article-title":"Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review","volume":"10","author":"Soriano","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.idnow.2025.105036_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1198926","article-title":"Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection","volume":"14","author":"Xiao","year":"2023","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.idnow.2025.105036_b0140","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jinf.2022.10.003","article-title":"Rapid emergence of ceftazidime-avibactam resistance among carbapenem-resistant Enterobacterales in a tertiary-care hospital in Taiwan","volume":"86","author":"Lee","year":"2023","journal-title":"J Infect"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991925000156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991925000156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T13:35:49Z","timestamp":1741700149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991925000156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2666991925000156"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2025.105036","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world use, effectiveness, and safety of ceftazidime-avibactam: Results of the French cohort OZAVIE","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2025.105036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"105036"}}